Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial. (linkinghub.elsevier.com)

Authors: Sehn LH … Trneny M Journal: The Lancet Published: 2026-01-10 DOI: https://doi.org/10.1016/S0140-6736(25)01778-7